Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in Pediatric HoFH
NCT04233918Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Maximum Observed Serum Concentration at Day 12, Area Under the Serum Concentration-Time Curve at Week 12 and 2 more. Started Jun 2020; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04233918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233918.